Dr. Anargyros Xenocostas

Dr. Anargyros Xenocostas


Consultant, Hematology

Current Practice:

Dr. Xenocostas is a Consultant in Hematology, Department of Medicine, at the London Health Sciences Centre as well as an Assistant Professor of Medicine at the University of Western Ontario.  He also holds a Cross Appointment as an Honourary Consultant in Hematology/Oncology at the LRCP.

Research Interests:

His research interests are centered on allogeneic Bone Marrow Transplantation.  They include the investigation of neuroprotective agents, the development of blood conservation strategies, and the study of long-term effects on neurocognitive function and quality of life issues in this population.


Dr. Xenocostas obtained his medical degree from McGill University, Montreal, and held a Transplant Fellowship at Princess Margaret Hospital and the University of Toronto in 2001/2002 under the supervision of Dr. Hans Messner.

Current Publications:

Allan DS, Gallacher L, Keeney M, Bhatia M, Chin-Yee I, Xenocostas A.

Undetectable leukemic blasts and absence of NOD/SCID leukemia-initiating cells in cord blood from a case of maternal AML.  Bone Marrow Transplant 2005 36(3):269-270.

Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelly M, Lutynski A, Crump M, Lipton JH, Kiss TL, Lau CY, Messner HA.  The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.  Eur J Clin Pharmacol 2005 61(3):189-95.

Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel MD, Xenocostas A, Kvietys P.  Erythropoietin prevents the acute myocardial inflammatory response induced by

ischemia/reperfusion via induction of AP-1.  Cardiovascular Research 2005. Feb 15, 65(3):719-27.

Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M.  Glycogen Synthase Kinase-3 is an in vivo regulator of hemopoietic stem cells.  Nature Medicine 2006 12(1):89-98.


Brisson A, Jason TLH, Xenocostas A, Berg RW.  Genomics based analysis of acute myeloid leukemia treatment resistance.  Poster presentation.  American Association for

Cancer research.  February 2005.

Lei M, Lou J, Lu X, Arnold MA, Xenocostas A, Feng Q.  Recombinant human erythropoietin enhances myocardial angiogenesis and attenuates cardiac remodeling in

mice post myocardial infarction.  FASEB J 2005, 19(5):A1323. Presented at XXXV

International Congress of Physiological Sciences and Experimental Biology, San Diego,

CA, April 4, 2005.

Helpful Links:


LHSCHealth Professionals

Virtual Orientation
LRCP Orientations
For New PatientsFor New Patients Glossary of TermsGlossary of Terms Quick LinksRecommended Sites Contact LRCPContact LRCP Parking, Maps, DirectionsParking, Maps, Directions Upcoming EventsUpcoming Events Canadian Cancer Society Cancer Care Ontario A Cancer Care Ontario Partner
Last Updated July 10, 2007 | © 2007, LHSC, London Ontario Canada